MapLight Therapeutics, Inc.
MPLT
Get informed when a big investor buys or sells
+ FollowMarket Cap$23.14M
Close$
$0.93
96.9% downside
Current Fair Value
96.9% downsideOvervalued by 96.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $23.14 Million |
|---|---|
| Enterprise Value | $-26,980,503.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.66 |
| Beta | 3.19 |
| Outstanding Shares | 45,276,763 |
Return
| Return on Equity | -49.89% |
|---|---|
| Return on Assets | -47.63% |
| Return on Invested Capital | -51.72% |
Valuation & Multiples
| P/E Ratio | -6.65 |
|---|---|
| PEG | -3.88 |
| Price to Sales | - |
| Price to Book Ratio | 3.76 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.13 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.21 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 3, 2026
EPS Estimate
$-0.92
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
June 25, 2026
EPS Estimate
$-1.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 56.11%▲ 0.43% |
|---|---|
| Total Invested | $502.15M▲ 23.95% |
| Investors Holding | 81▲ 7.00% |
ESG Score
No data
About MapLight Therapeutics, Inc.
109 employees
CEO: Christopher A. Kroeger MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /...